1,916 material Form 8-K filings that 1,609 companies we cover made with the SEC in July 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Aehr Test Systems reported fourth-quarter fiscal 2026 revenue of $18.8 million and GAAP net income of $1.4 million, compared with a net loss a year earlier, while full-year revenue fell to $50.0 million and the full-year GAAP net loss widened to $7.1 million. The company guided fiscal 2027 revenue to $130 million to $150 million, supported by an effective backlog of $100.6 million, which it said represents 2.6x to 3.0x fiscal 2026 revenue.
Q4 fiscal 2026 revenue was $18.8 million, up from $14.1 million a year earlier; GAAP net income was $1.4 million, or $0.04 per diluted share, versus a loss of $(0.10) per share.
Fiscal 2026 revenue was $50.0 million, down from $59.0 million; GAAP net loss was $(7.1) million, or $(0.23) per diluted share, versus $(3.9) million in fiscal 2025.
Record quarterly bookings of $60.7 million; effective backlog of $100.6 million as of the filing date.
Fiscal 2027 revenue guidance of $130 million to $150 million, implying approximately 160% to 200% year-over-year growth; cash, cash equivalents and restricted cash were $116.5 million at May 29, 2026.
California Resources Corporation said in a preliminary, unaudited update that its realized oil price for the three months ended June 30, 2026 was $76.50 per barrel after derivative settlements, versus $91.64 before them. The company estimates a $190 million loss from commodity derivatives for the quarter, and it warned that final results may differ and that the figures are not a quarterly earnings estimate.
Realized oil price with derivative settlements was $76.50 per barrel, compared with $91.64 without them.
Brent averaged $96.87 per barrel and WTI $92.79 per barrel for the quarter.
Estimated derivative loss of $190 million, including $164 million on commodity sales derivatives and $26 million on natural gas purchase derivatives.
The data is preliminary and unaudited and does not reflect all adjustments; the filing gives no earnings or revenue figures.
Virtu preliminarily estimated second-quarter 2026 trading income, net of $857 million, up from $653 million, while net income was $285 million, down from $293 million. Normalized Adjusted EPS rose to $1.82 from $1.53, but the estimates are unaudited and may change before final results on July 30, 2026. The same day, the company began marketing a $400 million add-on to its term loans, which would raise the term loan balance to $1,930 million.
Net income of $285 million vs. $293 million in Q2 2025; basic and diluted EPS of $1.63
Normalized Adjusted EPS of $1.82 vs. $1.53; Adjusted EBITDA of $437 million vs. $369 million
Trading income, net of $857 million vs. $653 million; Adjusted Net Trading Income of $718 million vs. $568 million
$400 million term loan add-on; commitments due July 16, 2026; final Q2 results due July 30, 2026
HCA Healthcare preliminarily reported second-quarter 2026 revenues of $20.230 billion and net income of $1.699 billion, or $7.62 per diluted share, both up from the year-earlier quarter. The company also lowered its 2026 net income and EPS guidance, citing a payer mix shift from health insurance exchange coverage losses, which shareholders should weigh against the stronger quarter. The preliminary figures are unaudited and subject to final quarterly closing procedures.
Q2 2026 revenues about $20.230 billion vs. $18.605 billion in Q2 2025; net income $1.699 billion ($7.62 per diluted share) vs. $1.653 billion ($6.83).
2026 diluted EPS guidance lowered to $28.70 to $30.50 from $29.10 to $31.50; net income guidance lowered to $6.300 billion to $6.700 billion from $6.495 billion to $7.035 billion.
Q2 unfavorable payer mix impact from exchange coverage losses estimated at about $400 million, partly offset by about $400 million of incremental Medicaid Supplemental Payment Program benefit.
Second-quarter earnings call scheduled for Friday, July 24, 2026, at 9:00 a.m. Central Time.
AngioDynamics reported fiscal 2026 results for the year ended May 31, 2026, with pro forma net sales up 9.4% to $320.2 million and Med Tech sales up 18.4% to $150.0 million. The GAAP net loss widened to $36.7 million, or $0.88 per share, from $34.0 million, or $0.83, a year earlier, and the company issued fiscal 2027 guidance calling for net sales of $336.0 million to $341.0 million and adjusted loss per share of $0.29 to $0.24.
Fourth-quarter pro forma net sales were $86.6 million, up 8.0%, but the GAAP loss per share was $0.27 versus $0.15 a year earlier.
Full-year adjusted EBITDA was $13.2 million, compared with $7.6 million in the prior year.
Fiscal 2027 guidance: net sales of $336.0 million to $341.0 million and adjusted EPS of ($0.29) to ($0.24), compared with fiscal 2026 adjusted loss per share of $0.24.
The company ended fiscal 2026 with $53.9 million in cash and states it has a debt-free balance sheet.
IBM released selected preliminary second-quarter 2026 results, saying its final figures could differ slightly. Revenue rose 1% to $17.2 billion, but Infrastructure revenue fell 7% and GAAP diluted EPS declined 2% to $2.27, while operating (non-GAAP) EPS rose 5% to $2.93. CEO Arvind Krishna said the quarter was below the company's expectations, mainly because numerous large deals failed to close on the expected timelines.
Revenue of $17.2 billion, up 1%; Software up 5%, Consulting flat, Infrastructure down 7%
GAAP diluted EPS of $2.27, down 2%; operating (non-GAAP) EPS of $2.93, up 5%
GAAP gross profit margin 57.7%, down 100 basis points; GAAP pre-tax income margin 14.4%, down 90 basis points
Management will discuss full-year expectations on the conference call on July 22, 2026, at 5:00 p.m. ET
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.